…
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Tilray Brands Inc is a global cannabis and consumer products company that cultivates, manufactures and distributes medical and adult-use cannabis, hemp-derived products and related consumer packaged goods in North America and international markets. Long-term growth may be supported by progressive legalization trends, expansion into new jurisdictions and efficiencies from larger production and branded offerings.
Principal investment risks are regulatory uncertainty across jurisdictions, intense competition and pricing pressure in the cannabis sector, and execution and profitability challenges as the company integrates operations and seeks sustainable cash flow.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -440.67M | -344.99M | -58.19M | -58.19M | -11.56M |
| Minority interest | -9.66M | -42.67M | 6.24M | 25.81M | 28.41M |
| Net income | -434.13M | -336.01M | -61.02M | -61.02M | -12.19M |
| Selling general administrative | 162.80M | 111.58M | 88.30M | 88.30M | 70.83M |
| Selling and marketing expenses | 65.86M | 44.12M | 29.92M | 29.92M | 20.67M |
| Gross profit | 116.82M | 123.18M | 137.68M | 137.68M | 55.74M |
| Reconciled depreciation | 130.15M | 115.19M | 18.65M | 15.85M | 3.56M |
| Ebit | 153.29M | -4.95M | -33.41M | 51.48M | -2.60M |
| Ebitda | 268.49M | 30.27M | 2.11M | 67.16M | 14.36M |
| Depreciation and amortization | 115.19M | 35.22M | 35.52M | 15.68M | 16.95M |
| Non operating income net other | - | - | -36.35M | - | -6.18M |
| Operating income | 153.29M | -4.95M | -47.62M | 51.48M | -2.60M |
| Other operating expenses | 856.92M | 581.64M | 389.07M | 389.07M | 222.44M |
| Interest expense | 39.68M | 30.90M | 24.78M | 24.78M | 5.75M |
| Tax provision | -7.18M | -6.54M | -5.60M | -8.45M | -4.45M |
| Interest income | 33.02M | 11.74M | 2.93M | 0.76M | 16.34M |
| Net interest income | -13.59M | -27.94M | -39.22M | -33.93M | -9.11M |
| Non recurring | - | - | 61.11M | - | - |
| Income tax expense | -6.54M | -8.97M | 2.82M | 2.82M | 0.63M |
| Total revenue | 628.37M | 513.09M | 391.00M | 391.00M | 175.25M |
| Total operating expenses | 345.37M | 191.74M | 135.75M | 135.75M | 102.94M |
| Cost of revenue | 511.56M | 389.90M | 253.31M | 253.31M | 119.50M |
| Total other income expense net | -593.97M | -340.04M | -10.57M | -109.68M | -8.96M |
| Net income from continuing ops | -1443.00M | -434.13M | -271.07M | -321.17M | -67.72M |
| Net income applicable to common shares | - | -434.13M | -271.07M | -321.17M | -67.72M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4307.26M | 5449.69M | 6025.36M | 1801.23M | 1801.23M |
| Intangible assets | 973.78M | 1277.88M | 1605.92M | 261.73M | 261.73M |
| Other current assets | 37.72M | 46.79M | 48.92M | 42.92M | 51.42M |
| Total liab | 977.32M | 1008.33M | 1560.05M | 475.89M | 475.89M |
| Total stockholder equity | 3315.69M | 4398.81M | 4459.07M | 1306.74M | 1306.74M |
| Deferred long term liab | - | - | - | 49.27M | - |
| Other current liab | 18.04M | 119.09M | 138.82M | 138.82M | 4.62M |
| Common stock | 0.07M | 0.05M | 0.05M | 1331.54M | 1331.54M |
| Capital stock | - | 0.07M | 0.05M | 0.05M | 1331.54M |
| Retained earnings | -2415.51M | -962.85M | -486.05M | -44.13M | -44.13M |
| Other liab | - | - | 196.83M | 53.89M | 59.02M |
| Good will | 2008.84M | 2641.30M | 2832.79M | 445.50M | 445.50M |
| Other assets | - | - | 111.51M | 4.36M | 7.86M |
| Cash | 206.63M | 415.91M | 488.47M | 358.47M | 358.47M |
| Total current liabilities | 432.98M | 280.34M | 401.24M | 122.84M | 122.84M |
| Current deferred revenue | 119.86M | - | 155.11M | 0.65M | 0.65M |
| Net debt | 383.50M | 207.90M | 450.19M | -58.15M | -58.15M |
| Short term debt | 224.26M | 92.65M | 49.60M | 7.44M | 7.44M |
| Short long term debt | - | 221.84M | 85.95M | 45.34M | 1.50M |
| Short long term debt total | 590.13M | 623.81M | 938.66M | 300.32M | 300.32M |
| Other stockholder equity | 5777.74M | 5382.37M | 4792.41M | 20.24M | 20.24M |
| Property plant equipment | - | - | 600.50M | 199.56M | 201.73M |
| Total current assets | 773.03M | 803.50M | 883.61M | 651.22M | 651.22M |
| Long term investments | - | 12.37M | 15.00M | 23.67M | 35.63M |
| Net tangible assets | - | - | 479.62M | 20.54M | -106.81M |
| Short term investments | 241.90M | 241.90M | - | 9.30M | 11.45M |
| Net receivables | 86.23M | 95.28M | 89.79M | 59.27M | 50.77M |
| Long term debt | - | 357.93M | 519.83M | 306.26M | 430.21M |
| Inventory | 200.55M | 245.53M | 256.43M | 190.56M | 190.56M |
| Accounts payable | 70.82M | 68.60M | 57.71M | 110.12M | 110.12M |
| Accumulated other comprehensive income | -46.61M | -20.76M | 152.67M | -0.91M | -0.91M |
| Common stock total equity | - | - | - | 1846.94M | 0.01M |
| Retained earnings total equity | - | - | - | -730.10M | - |
| Non currrent assets other | 0.22M | 111.51M | 8.29M | 8.29M | 0.00M |
| Non current assets total | 3534.23M | 4646.19M | 5141.75M | 1150.01M | 1150.01M |
| Capital lease obligations | - | 10.36M | 18.03M | 33.54M | 31.88M |
| Long term debt total | - | - | - | 306.26M | 444.36M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -285.11M | -21.53M | 0.30M | -253.18M | -44.88M |
| Change to liabilities | - | -44.65M | -30.76M | 20.00M | 14.64M |
| Total cashflows from investing activities | - | -21.53M | -41.68M | -253.18M | -98.62M |
| Net borrowings | - | -123.55M | 44.79M | -1.00M | 417.65M |
| Total cash from financing activities | 128.20M | 124.31M | 125.40M | 125.40M | 535.51M |
| Change to operating activities | - | 4.47M | -15.68M | -23.11M | 6.83M |
| Net income | -434.13M | -336.01M | -61.02M | -61.02M | -12.19M |
| Change in cash | -72.56M | 127.82M | -38.62M | -38.62M | 362.94M |
| Begin period cash flow | 488.47M | 360.65M | 397.09M | 397.09M | 44.15M |
| End period cash flow | 415.91M | 488.47M | 358.47M | 358.47M | 407.09M |
| Total cash from operating activities | -177.26M | -44.72M | -96.43M | -96.43M | -41.10M |
| Issuance of capital stock | 129.59M | 262.51M | 102.55M | 71.90M | 181.76M |
| Depreciation | 154.59M | 67.83M | 35.52M | 35.52M | 16.95M |
| Other cashflows from investing activities | - | - | 2.66M | -2.69M | -3.55M |
| Dividends paid | -7484.00M | - | - | - | - |
| Change to inventory | -45.75M | -35.29M | -90.25M | -90.25M | -29.17M |
| Change to account receivables | -5.84M | -23.51M | -24.73M | -24.73M | 9.21M |
| Sale purchase of stock | -1.19M | - | 96.97M | 111.52M | 228.65M |
| Other cashflows from financing activities | 7482.64M | 87.38M | 63.07M | 63.07M | 362.16M |
| Change to netincome | - | 236.72M | 183.10M | 157.98M | 29.32M |
| Capital expenditures | 34.06M | 38.87M | 95.47M | 95.47M | 152.23M |
| Change receivables | - | - | 6.29M | - | -16.41M |
| Cash flows other operating | - | - | -15.81M | - | -2.59M |
| Cash and cash equivalents changes | - | - | 93.82M | - | 486.13M |
| Change in working capital | -91.77M | -50.94M | -82.96M | -82.96M | -15.88M |
| Stock based compensation | 35.99M | 17.35M | 16.22M | 16.22M | 19.28M |
| Other non cash items | 185.59M | 281.92M | -2.24M | -2.24M | -46.23M |
| Free cash flow | -211.33M | -83.59M | -191.90M | -191.90M | -193.33M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLRY Tilray Inc |
0.02 0.71% |
2.83 | - | 1000.00 | 1.90 | 0.42 | 2.24 | -12.95 |
| MKKGY Merck KGaA ADR |
-0.24 0.72% |
33.16 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.88 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.24 1.13% |
20.95 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.85 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Irwin David Simon | Pres, CEO & Chairman | 1958 |
| Mr. Carl A. Merton CA, CBV, CPA | CFO & Principal Accounting Officer | 1970 |
| Mr. Mitchell S. Gendel | Global Gen. Counsel & Corp. Sec. | 1966 |
| Mr. James R. Meiers | Sr. VP of U.S. Operations | 1958 |
| Ms. Denise Menikheim Faltischek | Chief Strategy Officer & Head of International | 1973 |
| Mr. Lloyd Brathwaite | Chief Information Officer | NA |
| Mr. Roger Savell | Chief Admin. Officer | NA |
| Mr. John B. Sadler | VP of Investor Relations | NA |
| Ms. Dara S. Redler | Interim Chief Legal Officer & Corp. Sec. | NA |
| Mr. Bernard Yeung | Sr. VP of Sales & Marketing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.